CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.

Patterson BK, Seethamraju H, Dhody K, Corley MJ, Kazempour K, Lalezari J, Pang APS, Sugai C, Mahyari E, Francisco EB, Pise A, Rodrigues H, Wu HL, Webb GM, Park BS, Kelly S, Pourhassan N, Lelic A, Kdouh L, Herrera M, Hall E, Bimber BN, Plassmeyer M, Gupta R, Alpan O, O'Halloran JA, Mudd PA, Akalin E, Ndhlovu LC, Sacha JB

Open source

DOI
10.1016/j.ijid.2020.10.101
Published
2021 Feb
Container
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.ijid.2020.10.101,
  title = {CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.},
  author = {Patterson BK and Seethamraju H and Dhody K and Corley MJ and Kazempour K and Lalezari J and Pang APS and Sugai C and Mahyari E and Francisco EB and Pise A and Rodrigues H and Wu HL and Webb GM and Park BS and Kelly S and Pourhassan N and Lelic A and Kdouh L and Herrera M and Hall E and Bimber BN and Plassmeyer M and Gupta R and Alpan O and O'Halloran JA and Mudd PA and Akalin E and Ndhlovu LC and Sacha JB},
  year = {2021},
  journal = {International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases},
  doi = {10.1016/j.ijid.2020.10.101},
  url = {https://doi.org/10.1016/j.ijid.2020.10.101}
}

RIS

TY  - JOUR
TI  - CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.
AU  - Patterson BK
AU  - Seethamraju H
AU  - Dhody K
AU  - Corley MJ
AU  - Kazempour K
AU  - Lalezari J
AU  - Pang APS
AU  - Sugai C
AU  - Mahyari E
AU  - Francisco EB
AU  - Pise A
AU  - Rodrigues H
AU  - Wu HL
AU  - Webb GM
AU  - Park BS
AU  - Kelly S
AU  - Pourhassan N
AU  - Lelic A
AU  - Kdouh L
AU  - Herrera M
AU  - Hall E
AU  - Bimber BN
AU  - Plassmeyer M
AU  - Gupta R
AU  - Alpan O
AU  - O'Halloran JA
AU  - Mudd PA
AU  - Akalin E
AU  - Ndhlovu LC
AU  - Sacha JB
PY  - 2021
JO  - International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
DO  - 10.1016/j.ijid.2020.10.101
UR  - https://doi.org/10.1016/j.ijid.2020.10.101
ER  - 

APA

BK, P., H, S., K, D., MJ, C., K, K., J, L., APS, P., C, S., E, M., EB, F., A, P., H, R., HL, W., GM, W., BS, P., S, K., N, P., A, L., L, K., M, H., E, H., BN, B., M, P., R, G., O, A., JA, O., PA, M., E, A., LC, N., & JB, S. (2021). CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14.. International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases. https://doi.org/10.1016/j.ijid.2020.10.101

Source records